Evidence map›Paper›PMID 30375490›Full record

ReviewLeukemia2018

Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms.

Mariusz Z Ratajczak, Kamila Bujko, Aaron Mack, Magda Kucia, Janina Ratajczak

Erratum issuedOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 76 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. A different perspective on the cancer stem cell theory.Medical oncology (Northwood, London, England) · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Mariusz Z RatajczakStem Cell Institute, Division of Hematology and Oncology, James Graham Brown Cancer Center, University Louisville, 500 South Floyd Street, Louisville, 40202, Kentucky, USA. mzrata01@louisville.edu.
Kamila BujkoStem Cell Institute, Division of Hematology and Oncology, James Graham Brown Cancer Center, University Louisville, 500 South Floyd Street, Louisville, 40202, Kentucky, USA.
Aaron MackStem Cell Institute, Division of Hematology and Oncology, James Graham Brown Cancer Center, University Louisville, 500 South Floyd Street, Louisville, 40202, Kentucky, USA.
Magda KuciaStem Cell Institute, Division of Hematology and Oncology, James Graham Brown Cancer Center, University Louisville, 500 South Floyd Street, Louisville, 40202, Kentucky, USA.
Janina RatajczakStem Cell Institute, Division of Hematology and Oncology, James Graham Brown Cancer Center, University Louisville, 500 South Floyd Street, Louisville, 40202, Kentucky, USA.
James Graham Brown Foundation · US

Funding

Novel mechanisms involving complement cascade in stem cell traffickingR01DK074720 · NIDDK · UNIVERSITY OF LOUISVILLE · PI RATAJCZAK, MARIUSZ Z · 2007 to 2020
$4.1M
BIOACTIVE LIPIDS IN STEM CELL HOMING AND MOBILIZATIONR01HL112788 · NHLBI · UNIVERSITY OF LOUISVILLE · PI RATAJCZAK, MARIUSZ Z · 2013 to 2016
$1.5M
Current Trends in Stem Cell TherapiesT32HL134644 · NHLBI · UNIVERSITY OF LOUISVILLE · PI KAKAR, SHAM S., RATAJCZAK, MARIUSZ Z · 2017 to 2021
$1.4M
NHLBI NIH HHS R01 HL112788NHLBI NIH HHS T32 HL134644NIDDK NIH HHS R01 DK074720
6 · The paper itself

Abstract

Tumorigenesis can be considered as pathologically misappropriated tissue regeneration. In this review we will address some unresolved issues that support this concept. First, we will address the issue of the identity of cancer-initiating cells and the presence of cancer stem cells in growing tumors. We will also ask are there rare and distinct populations of cancer stem cells in established tumor cell lines, or are all of the cells cancer stem cells? Second, the most important clinical problem with cancer is its metastasis, and here a challenging question arises: by employing radio-chemotherapy for tumor treatment, do we unintentionally create a prometastatic microenvironment in collateral organs? Specifically, many factors upregulated in response to radio-chemotherapy-induced injury may attract highly migratory cancer cells that survived initial treatment. Third, what is the contribution of normal circulating stem cells to the growing malignancy? Do circulating normal stem cells recognize a tumor as a hypoxia-damaged tissue that needs vascular and stromal support and thereby contribute to tumor expansion? Fourth, is it reasonable to inhibit only one prometastatic ligand-receptor axis when cancer stem cells express several receptors for several chemotactic factors that may compensate for inhibition of the targeted receptor? Fifth, since most aggressive cancer cells mimic early-development stem cells, which properties of embryonic stem cells are retained in cancer cells? Would it be reasonable to inhibit cancer cell signaling pathways involved in the migration and proliferation of embryonic stem cells? We will also briefly address some new players in cancerogenesis, including extracellular microvesicles, bioactive phospholipids, and extracellular nucleotides.

Indexed as

AnimalsCarcinogenesisCell MovementHumansNeoplasmsNeoplastic Stem CellsRegenerationSignal TransductionTumor MicroenvironmentUp-Regulation

Identifiers

PMID30375490
PMCPMC6286324
OpenAlexW2898935222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.